RTW Biotech Opportunities Ltd USD
RTW.L
London Stock Exchange2.05
USD
-0.01
(-0.49%)
RTW Biotech Opportunities Ltd USD
RTW.L
(London Stock Exchange)
Recent
price
2.05
P/E
ratio
-7.88
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- RTW Biotech Opportunities Ltd (RTW.L) is a Guernsey-domiciled closed-end investment company that identifies and invests in transformative assets with high growth potential across the life sciences, biopharmaceutical, and medical technology sectors; it targets companies developing next-generation therapies and technologies, including genetic medicines, biologics, small molecule pharmaceuticals, antibodies, and medical devices, to improve patient outcomes and extend lives. The fund pursues a full life-cycle investment strategy, supporting opportunities from early-stage academic programs and private ventures through to mature public companies, with a diversified core portfolio comprising private and public holdings, royalties via the 4010 Royalty Fund, and other public investments; it operates globally, with primary exposure to the United States, Europe (including the Netherlands and United Kingdom), and China, and maintains offices in New York and London under the management of RTW Investments, LP. Founded in 2019 and listed on the London Stock Exchange's Main Market, the company is headquartered at 1st Floor, Royal Chambers, St Peter Port, Guernsey. In recent developments, RTW Biotech completed its transformational all-share acquisition of Arix Bioscience in February 2024, significantly expanding scale, liquidity, and portfolio with six new positions; the core portfolio added 21 new companies in 2024, including ten privates, one RTW-incubated entity, and four reclassified publics, amid three IPOs, one acquisition, and one reverse merger; portfolio highlights included Bayer AG's investment in and strategic collaboration with RTW-founded Corxel (formerly Ji Xing Pharmaceuticals) on cardiovascular assets in China, plus participation in Aquestive Therapeutics' $75 million funding via the 4010 Royalty Fund to support its Anaphylm epinephrine product.